New pyrimidine-5-carbonitriles as COX-2 inhibitors: Design, synthesis, anticancer screening, molecular docking, and in silico ADME profile studies

Hanan A. AL-Ghulikah[1], Samiha A. El-Sebaey[2*], Amr K. A. Bass [3], Mona S. El-Zoghbi [3]

[1]Department of Chemistry, College of Sciences, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia

[2] Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy (Girls), Al-Azhar University, Youssef Abbas Street, Nasr City, Cairo, Egypt

[3] Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Menoufia University, Menoufia, Shibin-Elkom, Gamal Abd Al-Nasir Street, Egypt

Corresponding author mail: samiha.ali85@azhar.edu.eg



Figure S1. ^{1}H NMR of compound **3a**.



Figure S2. ^{13}C NMR of compound **3a**.

S3



Figure S3. Mass of compound **3a**.



Figure S4. ^{1}H NMR of compound **3b**.

S5



Figure S5. ^{13}C NMR of compound **3b**.



Figure S6. ^{1}H NMR of compound **3c.**



Figure S7. ^{13}C NMR of compound **3c**.



Figure S8. ^{1}H NMR of compound **3d**.



Figure S9 .^{13}C NMR of compound **3d**.



Figure S10. ^{1}H NMR of compound **5a**.



Figure S11. ^{13}C NMR of compound **5a.**



Figure S12. Mass of compound **5a.**



Figure S13. ^{1}H NMR of compound **5b**.



Figure S14. ^{13}C NMR of compound **5b**.



Figure S15. ^{1}H NMR of compound **5c**.



Figure S16. ^{13}C NMR of compound **5c**.



Figure S17. ^{1}H NMR of compound **5d**.



Figure S18. ^{13}C NMR of compound **5d**.